New AGC Biologics facility in Yokohama strengthens access to world-class biomanufacturing in Japan, offering mammalian, mRNA and cell therapy services The two FlexFactory manufacturing platforms grow AGC Biologics’ capacity for… Read More
Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper… Read More
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway… Read More
Members of the UBC faculty of medicine community are working with community partners to address priority issues across B.C. through support from the 2023-24 Community-University Engagement Support (CUES) Fund for projects…. Read More
OTTAWA, ON – Innovative Medicines Canada (IMC) remains concerned that the government’s proposed pharmacare model will not increase access to new medicines for Canadians, who currently have slower and more limited… Read More
